A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus

• Published in: Transplantation Vol. 67; no. 4; pp. 641 - 643
• Main Authors: Kessler, M, Champigneulles, J, Hestin, D, Frimat, L, Renoult, E
• Format: Journal Article
• Language: English
• Published: United States 27-02-1999
• Subjects: Adolescent; Cyclosporine - therapeutic use; Glomerulosclerosis, Focal Segmental - etiology; Humans; Immunosuppressive Agents - adverse effects; Kidney Transplantation; Male; Recurrence; Tacrolimus - adverse effects; Transplantation, Homologous
• ISSN: 0041-1337
• DOI: 10.1097/00007890-199902270-00030

Focal and segmental glomerulosclerosis (FSGS) is one of the most frequent and severe primary glomerulonephritis that recurs in transplanted kidneys. Although cyclosporine seems to have no effect on the frequency of FSGS recurrence, there is evidence that cyclosporine reduces proteinuria and prolongs graft survival in patients with recurrent glomerulonephritis after renal transplantation. The effect of tacrolimus on nephrotic syndrome after renal transplantation is controversial.
We describe the case of a 30-year-old man with steroid-resistant nephrotic syndrome due to FSGS who developed nephrotic syndrome 5 years after renal transplantation due to recurrent disease when he was switched from cyclosporine to tacrolimus.
He was given pulses of methylprednisolone and returned to cyclosporine. His proteinuria decreased, but he rapidly developed chronic renal failure.
This observation strongly suggests that tacrolimus should be given with considerable care in renal transplant recipients with FSGS.